Literature DB >> 26872581

In vitro hemocompatibility testing: The importance of fresh blood.

Sjoerd Leendert Johannes Blok1, Gerwin Erik Engels1, Willem van Oeveren2.   

Abstract

The use of unactivated blood for hemocompatibility testing is essential to obtain reliable results. Here, the authors study the influence of heparinized whole blood storage time and temperature on blood activation and evaluate the importance of initiating hemocompatibility tests within 4 h of blood collection. Blood from healthy volunteers was collected and analyzed with minimal delay, after 30 min and after 60 min of storage at room temperature, 30 or 37 °C. In addition, blood was analyzed after 1, 2, or 4 h of storage at room temperature. Platelet count, mean platelet volume, platelet binding capacity to collagen and thromboxane B2 were measured to assess platelet function, complement complex C5b-9 and elastase were measured to assess activation of the inflammatory response system, and thrombin-antithrombin III was measured to assess activation of the coagulation system. Furthermore, free hemoglobin was measured in platelet poor plasma as an indicator for red blood cell damage. The authors found that storage at 30 °C significantly increased platelet and coagulation activity after 60 min and storage at 37 °C significantly increased platelet, coagulation, and white blood cell activity after 60 min. Storage at room temperature significantly decreased platelet binding to collagen after 4 h and increased platelet activity after 1 h onward and white blood cell activity after 4 h. Their results show that short-term storage of heparinized whole blood significantly influences biomarkers over time, especially at 30 and 37 °C compared to room temperature. However, blood stored at room temperature for 4 h is also affected. In particular, platelet function and white blood cell activity are significantly influenced after 4 h of stationary storage at room temperature; therefore, the authors propose that hemocompatibility tests should be initiated well within 4 h of blood collection, preferably within 2 h.

Entities:  

Mesh:

Year:  2016        PMID: 26872581     DOI: 10.1116/1.4941850

Source DB:  PubMed          Journal:  Biointerphases        ISSN: 1559-4106            Impact factor:   2.456


  8 in total

Review 1.  In Vitro models for thrombogenicity testing of blood-recirculating medical devices.

Authors:  Deepika N Sarode; Shuvo Roy
Journal:  Expert Rev Med Devices       Date:  2019-06-10       Impact factor: 3.166

2.  In-Vitro Visualization of Thrombus Growth in Artificial Lungs Using Real-Time X-Ray Imaging: A Feasibility Study.

Authors:  Andreas Kaesler; Freya Lilli Rudawski; Mark Oliver Zander; Felix Hesselmann; Isaac Pinar; Thomas Schmitz-Rode; Jutta Arens; Ulrich Steinseifer; Johanna Charlotte Clauser
Journal:  Cardiovasc Eng Technol       Date:  2021-09-16       Impact factor: 2.305

3.  Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior.

Authors:  Catarina Santos; Suzy Turiel; Pedro Sousa Gomes; Elísio Costa; Alice Santos-Silva; Paulo Quadros; José Duarte; Sílvia Battistuzzo; Maria Helena Fernandes
Journal:  J Nanobiotechnology       Date:  2018-03-22       Impact factor: 10.435

4.  Capillary flow-driven microfluidic device with wettability gradient and sedimentation effects for blood plasma separation.

Authors:  M Sneha Maria; P E Rakesh; T S Chandra; A K Sen
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

Review 5.  Blood-Contacting Biomaterials: In Vitro Evaluation of the Hemocompatibility.

Authors:  Marbod Weber; Heidrun Steinle; Sonia Golombek; Ludmilla Hann; Christian Schlensak; Hans P Wendel; Meltem Avci-Adali
Journal:  Front Bioeng Biotechnol       Date:  2018-07-16

6.  The optimal incubation time for in vitro hemocompatibility testing: Assessment using polymer reference materials under pulsatile flow with physiological wall shear stress conditions.

Authors:  Sjoerd Leendert Johannes Blok; Willem van Oeveren; Gerwin Erik Engels
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2019-01-29       Impact factor: 3.368

Review 7.  Synthesis and compatibility evaluation of versatile mesoporous silica nanoparticles with red blood cells: an overview.

Authors:  Subhankar Mukhopadhyay; Hanitrarimalala Veroniaina; Tadious Chimombe; Lidong Han; Wu Zhenghong; Qi Xiaole
Journal:  RSC Adv       Date:  2019-11-01       Impact factor: 4.036

8.  In vitro methodology for medical device material thrombogenicity assessments: A use condition and bioanalytical proof-of-concept approach.

Authors:  Michael F Wolf; Gaurav Girdhar; Arielle A Anderson; Samantha R Ubl; Sinduja Thinamany; Hannah N Jeffers; Courtney E DeRusha; Jenny Rodriguez-Fernandez; Sebastian Hoffmann; Carrie A Strief
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2020-09-14       Impact factor: 3.368

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.